Trial Design

DOI: 10.4244/EIJ-D-24-00100

Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial

Ashley Verburg1,2, MD; Wilbert L. Bor1, MD; I. Tarik Küçük3, MD; José P.S. Henriques3, MD, PhD; Maarten A. Vink4, MD, PhD; Willem-Peter T. Ruifrok5, MD, PhD; Jacobus Plomp6, MD; Ton A.C.M. Heestermans7, MD, PhD; Carl E. Schotborgh8, MD; Pieter J. Vlaar9, MD, PhD; Michael Magro10, MD, PhD; Sem A.O.F. Rikken1,2, MD; Wout W.A. van den Broek1, MD; Carlos A.G. van Mieghem11, MD, PhD; Kristoff Cornelis12, MD; Liesbeth Rosseel13, MD; Karl S. Dujardin14, MD; Bert Vandeloo15, MD; Tom Vandendriessche16, MD; Bert Ferdinande17, MD; Arnoud W.J. van ’t Hof18,19, MD, PhD; Jan G.P. Tijssen20, PhD; Ugo Limbruno21, MD, PhD; Raffaele De Caterina22,23, MD, PhD; Andrea Rubboli24, MD; Dominick J. Angiolillo25, MD, PhD; Tom Adriaenssens26, MD, PhD; Willem Dewilde27, MD, PhD; Jurrien M. ten Berg1,18, MD, PhD

Abstract

The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) remains unclear. Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor – preferably clopidogrel) after a short course of triple antithrombotic therapy (TAT; DAT plus aspirin). Although DAT reduces bleeding risk compared to TAT, this is counterbalanced by an increase in ischaemic events. Aspirin provides early ischaemic benefit, but TAT is associated with an increased haemorrhagic burden; therefore, we propose a 30-day dual antiplatelet therapy (DAPT; aspirin plus P2Y12 inhibitor) strategy post-PCI, temporarily omitting OAC. The study aims to compare bleeding and ischaemic risk between a 30-day DAPT strategy following PCI and a guideline-directed therapy in AF patients requiring OAC. WOEST-3 (ClinicalTrials.gov: NCT04436978) is an investigator-initiated, international, open-label, randomised controlled trial (RCT). AF patients requiring OAC who have undergone successful PCI will be randomised within 72 hours after PCI to guideline-directed therapy (edoxaban plus P2Y12 inhibitor plus limited duration of aspirin) or a 30-day DAPT strategy (P2Y12 inhibitor plus aspirin, immediately discontinuing OAC) followed by DAT (edoxaban plus P2Y12 inhibitor). With a sample size of 2,000 patients, this trial is powered to assess both superiority for major or clinically relevant non-major bleeding and non-inferiority for a composite of all-cause death, myocardial infarction, stroke, systemic embolism or stent thrombosis. In summary, the WOEST-3 trial is the first RCT temporarily omitting OAC in AF patients, comparing a 30-day DAPT strategy with guideline-directed therapy post-PCI to reduce bleeding events without hampering efficacy.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 14
Jul 15, 2024
Volume 20 Number 14
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV16I2A18 Jun 12, 2020
Dropping P2Y12 inhibitors in patients with AF undergoing PCI? Not yet a SAFE bet
Lopes RD and Fanaroff A
free

10.4244/EIJV13I5A95 Aug 4, 2017
Will PIONEER AF-PCI change my practice?
Ukena C et al
free

10.4244/EIJV15I12A192 Dec 20, 2019
GLOBAL LEADERS: looking now at the bigger picture
Guedeney P and Montalescot G
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved